论文部分内容阅读
目的探讨P16、P53、Bcl2表达,Ki67标记指数与胸腺瘤侵袭性及预后的关系。方法应用免疫组化染色方法检测41例胸腺瘤患者P16、P53、Bcl2、Ki67的表达。结果胸腺瘤P16、P53、Bcl2阳性表达率分别为488%、585%、415%,Ki67标记指数(Ki67LI)为955%±675%。P16、Bcl2蛋白表达与胸腺瘤的侵袭性和预后均无关系。P53蛋白表达和Ki67LI与胸腺瘤侵袭性相关(P<005,P<001),Ki67LI还与胸腺瘤预后有关(P<005)。结论P53蛋白表达和Ki67LI可为侵袭性胸腺瘤诊断提供依据,Ki67LI还可作为估计胸腺瘤预后的参考指标。
Objective To investigate the relationship between the expression of P16, P53 and Bcl2, the Ki67 labeling index and the invasiveness and prognosis of thymoma. Methods Immunohistochemical staining was used to detect the expression of P16, P53, Bcl2 and Ki67 in 41 patients with thymoma. Results The positive rates of P16, P53 and Bcl2 in thymoma were 488%, 585% and 415%, respectively. The Ki67 labeling index (Ki67LI) was 955% ± 675%. P16, Bcl2 protein expression and thymoma invasion and prognosis are not related. P53 protein expression and Ki67LI were associated with thymoma invasiveness (P <005, P <001). Ki67LI was also associated with the prognosis of thymoma (P <0.05). Conclusions The expression of P53 protein and Ki67LI can provide the basis for the diagnosis of invasive thymoma. Ki67LI can be used as a reference index for estimating the prognosis of thymoma.